Survival in Systemic Sclerosis With Pulmonary Arterial Hypertension Has Not Improved in the Modern Era.

The article discusses a study which examined the impact of modern therapy on survival in pulmonary arterial hypertension (PAH) and associated systemic sclerosis. It also aimed to determine associations among commonly used clinical and hemodynamic variables, treatment, and long-term survival in PAH associated with SSc compared with PAH defined as idiopathic, familial, or associated with anorexigens. It concluded that mortality in SSc has not improved since the introduction of epoprostenol.